Johnson & Johnson (NYSE:JNJ - Free Report) - Investment analysts at Leerink Partnrs cut their Q2 2024 earnings estimates for Johnson & Johnson in a research report issued on Wednesday, April 17th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $2.73 per share for the quarter, down from their prior forecast of $2.75. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.65 per share. Leerink Partnrs also issued estimates for Johnson & Johnson's FY2027 earnings at $12.21 EPS.
JNJ has been the topic of several other research reports. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an "outperform" rating in a report on Wednesday, January 3rd. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Royal Bank of Canada dropped their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday. Finally, HSBC upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating and raised their target price for the stock from $169.00 to $170.00 in a report on Thursday. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $175.86.
Read Our Latest Report on JNJ
Johnson & Johnson Stock Performance
JNJ stock traded up $0.97 on Thursday, hitting $145.74. The company had a trading volume of 9,867,856 shares, compared to its average volume of 7,254,172. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The stock's 50-day simple moving average is $156.32 and its 200 day simple moving average is $155.68. The stock has a market cap of $351.20 billion, a price-to-earnings ratio of 9.09, a P/E/G ratio of 2.40 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The firm had revenue of $21.38 billion for the quarter, compared to analysts' expectations of $21.39 billion. During the same quarter in the prior year, the company posted $2.68 earnings per share. The business's revenue for the quarter was up 2.3% on a year-over-year basis.
Institutional Trading of Johnson & Johnson
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hibernia Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $27,000. FNY Investment Advisers LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at about $37,000. Tower View Wealth Management LLC grew its holdings in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company's stock valued at $40,000 after purchasing an additional 165 shares during the last quarter. Keener Financial Planning LLC bought a new position in Johnson & Johnson during the 4th quarter valued at about $40,000. Finally, WFA Asset Management Corp grew its holdings in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company's stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.
Insider Activity
In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.40%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson's dividend payout ratio (DPR) is presently 29.68%.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
